Juxtapid
Payments companies reported to CMS as associated with Juxtapid. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Juxtapid, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Juxtapid
These are the largest totals companies reported as associated with Juxtapid. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Eliot Brinton | Salt Lake City, UT | Endocrinology, Diabetes & Metabolism | $43,340.89 |
| Archna Bajaj | Philadelphia, PA | Internal Medicine | $18,498.86 |
| Ambika Ashraf | Birmingham, AL | Pediatric Endocrinology | $15,118.84 |
| Gregory Pokrywka | Towson, MD | Internal Medicine | $8,037.37 |
| Donnie Wilson | Fort Worth, TX | Pediatric Endocrinology | $6,879.72 |
| James Underberg | New York, NY | Internal Medicine | $5,918.32 |
| Julie Brothers | Philadelphia, PA | Pediatric Cardiology | $4,000.00 |
| Paul Duell | Portland, OR | Endocrinology, Diabetes & Metabolism | $2,000.00 |
| Robert Palermo | Allentown, PA | Pediatric Cardiology | $1,975.00 |
| Martin Thelin | San Francisco, CA | Pediatric Endocrinology | $1,940.80 |
Prescribed Juxtapid?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.